Life Science Nation Newsletter  | November 2,  2017  |  Issue 238


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Oct. 26  - Nov. 1)
Invests Broadly in Healthcare Companies, Focuses on Oncology
Seeking Companies with China Angle
Seeking Material-Based Life Science Technologies
Invests in Therapeutics, Medical Devices, Diagnostics
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Cole Bunn, Senior Research Analyst, LSN

We are excited to showcase the top 36 innovation challenge startups from the first ever RESI conference to be held in New York City. These handpicked companies represent the key sectors of the healthcare space including therapeutics, medical devices, diagnostics and healthcare IT and were selected based on their scientific/technical merit and commercial viability.

The Innovation Challenge companies will compete for each attendee's RESI Cash tokens throughout the day, which serves as a vote of their potential. The top 3 companies will win additional RESI tickets to events of their choosing, giving them access to hundreds of additional investors and ultimately enhancing their likelihood of securing an investment. Make sure to visit the exhibition hall to meet the RESI innovators and "invest" in your favorites!

Therapeutic
Medical Device

Diagnostic
Healthcare IT
By Christine A. Wu, Senior Research Analyst, LSN

Venture philanthropic foundations have deep expertise that is often overlooked. Each foundation has a specific, genuine mission towards a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking "positively impactful" technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

New York City is home to a great number of life science foundations. LSN has dedicated the Venture Philanthropy panel to the following five incredible Foundations for the RESI New York City Conference on November 15th. Moderated by John Walter, CEO and President of Alliance for Cancer Gene Therapy, the audience will have an exclusive opportunity to hear from:
  • Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson's Research
  • Michael Batten, Director, Strategic Partnerships, Juvenile Diabetes Research Foundation (JDRF) T1D Fund
  • Ken LaMontagne, VP of Research, Therapy Acceleration Program, Leukemia & Lymphoma Society
  • Andres Hurtado-Lorenzo, Director of Translational Research, Crohn's and Colitis Foundation
Meet The Family Offices that Invest Directly in Biotech, Medtech and Healthcare IT Startups
By Lucy Parkinson, Diretor of Research, LSN

RESI has always aimed to feature a diverse variety of investors, and every RESI event has included a Family Offices panel discussion. It's proved to be a field of continuing interest for entrepreneurs, because life science companies often need the patient capital and deep connections that a family office investor can offer. Family offices are highly idiosyncratic, and many have a specific investment strategy or area of domain expertise that guides their life science investments; in some cases, they've developed scientific expertise in a disease that affects a family member. With many different motivations and strategies to deploy, these investors are an increasingly significant constituency in the life sciences.

For RESI NYC, we've gathered family offices that invest in several different life science verticals. If you'd like to hear more about what they're interested in and how they make decisions, you can join us at RESI NYC to hear from our panel moderator, Ron Paliwoda, Founder and President, Paliwoda Group, and the panelists:
  • Chuck Stetson, CEO, Stetson Family Office
  • Sherry Grisewood, Chief Investment Officer, FoxHill Asset Management
  • Mark Groner, Vice President, Sopris Capital
  • Kevin Schimelfenig, Managing Partner and CEO, McGeever LLC

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics